Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Familial Adenomatous Polyposis Clear all
Terminated No phase listed Observational Results available

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

NCT00151476
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
Celecoxib, Routine Medical Care
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting No phase listed Observational

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

NCT04677998
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Personalized surveillance and intervention protocol
Procedure
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Terminated Phase 3 Interventional Results available

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

NCT00585312
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
23
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 25, 2026, 8:06 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

NCT04230499
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Encapsulated Rapamycin (eRapa)
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

NCT00685568
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years to 14 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

NCT03649971
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

NCT05014360
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
JNJ-64251330
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 25, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program

NCT02747862
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Deleterious Familial Adenomatous Polyposis
Interventions
Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 25, 2026, 8:06 AM EDT
Terminated No phase listed Observational

Non-Invasive Prediction of Colorectal Neoplasia

NCT01815463
View directory record Official record
Conditions
Colonic Polyps, Polyposis Coli, Colorectal Cancer
Interventions
Not listed
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
2,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

NCT05552755
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
REC-4881, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Not applicable Interventional

Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)

NCT00525655
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Colorectal Cancer
Interventions
Web-Based Multimedia Intervention, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Curcumin in Treating Patients With Familial Adenomatous Polyposis

NCT00641147
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Curcumin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Results available

Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)

NCT00770991
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Black raspberry (BRB) Slurry, Black Raspberry (BRB) Suppositories, Black Raspberry (BRB) Placebo Slurry
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting Phase 1 Interventional

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

NCT05630794
View directory record Official record
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions
Tegavivint
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting Not applicable Interventional

Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)

NCT06641310
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Exercise Therapy
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Completed No phase listed Observational

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer

NCT00675636
View directory record Official record
Conditions
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
Interventions
study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 25, 2026, 8:06 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

NCT00033371
View directory record Official record
Conditions
Colorectal Cancer, Familial Adenomatous Polyposis
Interventions
Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 25, 2026, 8:06 AM EDT
Terminated No phase listed Observational

Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01

NCT04674228
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Electronic Health Record Review
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

CryoBalloon Ablation for Treatment of Duodenal Adenomas

NCT03847636
View directory record Official record
Conditions
Duodenal Adenomas, Familial Adenomatous Polyposis
Interventions
CryoBalloon ablation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Manhasset, New York • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 8:06 AM EDT
Enrolling by invitation Not applicable Interventional

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

NCT06578637
View directory record Official record
Conditions
FAP, Familial Adenomatous Polyposis
Interventions
R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B)
Dietary Supplement
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 8:06 AM EDT